InvestorZone

Hamps Bio Limited IPO

About Company—

Hamps Bio Limited is engaged in two primary business activities:

Pharmaceutical Formulations (Pharma Segment)

- The company is involved in the ethical marketing and distribution of pharmaceutical formulation products under its brand name "Hamps."
- These products include various dosage forms such as tablets, syrups, capsules, injectables, oils, gels, and powders.
- Company procures products with various contract manufacturers who

Segment wise revenue—

Particulars	For the period ended October 31, 2024		Fiscal 2024		Fiscal 2023		Fiscal 2022	
	Revenue	% of	Revenue	% of	Revenue	% of	Revenue	% of
	from	Revenue	from	Revenue	from	Revenue	from	Revenue
	Operations		Operations		Operations		Operations	
	(₹ in Lakhs)		(₹ in Lakhs)		(₹ in Lakhs)		(₹ in Lakhs)	
Pharma	211.64	49.60	366.43	56.59	377.77	67.72	393.15	73.62
FDFP	215.03	50.40	281.10	43.41	180.05	32.28	140.89	26.38
Total	426.67	100	647.53	100.00	557.81	100.00	534.05	100.00

Company also exports FDFP products. For the period ended Oct 31st, 2024 22.54% of revenue was generated from exports.

Objects of the Issue-

have WHO GMP approved manufacturing plant facilities. Such contract manufacturers produce pharmaceutical products on company's behalf based on compositions given by the company and subsequently market those products under the brand HAMPS.

Freeze Dried and Frozen Products (FDFP)

- Hamps Bio manufactures freeze-dried and frozen products, such as fruits, vegetables, herbs, and flowers, under the brand "FzyEzy."
- Company business model for FDFP product is based on the following approaches:

Contract Manufacturing: Customers place the orders with Hampd Bio with their specification and company produces as a white labelling to develop products suitable for the customers' brands

Own Brand: Company sell their own FDFP products under its own brand through distribution network and ecommerce platform.

Financials

(Fig in Cr)

- Purchase of Plant and Machinery amounting Rs. 3.59 Crore. Currently the company is working at full capacity. This capex will increase the capacity of the company.
- Enhancing the visibility and awareness of our brand by incurring expenditure on advertisement, Business Promotion, Marketing & other expenses: Rs.0.50 Crore.
- General Corporate Purpose: Rs. 1.51 Crore.

IPO details and Valuation-

- Fresh Issue: Rs.6.22 Cr.
- Price Band: Rs. 51
- Lot Size: 2,000 shares.
- Market Cap: Rs.22.22 Cr.
- FY 24 PAT: Rs.0.50 Cr.
- P/E: 44.44

Positive and Negative Points—

Particulars	Oct 31st, 2024	FY'24	FY'23	FY'22
Revenue	4.26	6.47	5.57	5.34
Revenue Growth		16.16%	4.31%	
EBITDA	0.65 (15.32%)	1.17 (18.18%)	0.86 (15.53%)	0.61 (11.52%)
PAT	0.34 (7.99%)	0.50 (7.73%)	0.35 (6.44%)	0.12 (2.28%)
D/E Ratio	0.37	0.31	1.27	2.03
RONW	9.19%	14.84%	26.34%	12.08%
CFOA	0.74	(0.29)	1.22	0.33

Positive

- Entire issue is Fresh Issue i.e., IPO funds will be infused in the company for the company's growth.
- Manageable debts.

Negative

- No such growth in revenue.
- The company operates on a relatively small scale. Company having revenue of Just Rs. 6.47 Cr. with PAT of Rs. 0.50 Cr. in FY 24 is launching its IPO.
- Stretched valuation with PE of 44.44

Comparison with Peers—

As per RHP no listed peers of the company.

0





Disclaimer: The information provided regarding this IPO is intended solely for educational purposes. It should not be construed as financial advice, an endorsement, or a recommendation to invest. Potential investors are encouraged to conduct their own research and consult with a financial advisor before making any investment decisions. Investing in securities involves risks, and it is important to carefully consider all aspects before committing any capital.